REPURPOSE: PHASE II STUDY ASSESSING THE EFFICACY OF EFAVIRENZ, AN APPROVED HIV DRUG REPURPOSED AS AN ANTI-CANCER AGENT, IN PATIENTS WITH PLATINUM RESISTANT OVARIAN CANCER